Valuation: Jade Biosciences, Inc.

Market Cap 1.28B 1.12B 1.03B 956M 1.81B 122B 1.84B 12.31B 4.79B 59.76B 4.79B 4.69B 206B P/E 2026 *
-8.27x
P/E 2027 * -8.35x
Enterprise Value 1.02B 895M 822M 766M 1.45B 97.43B 1.48B 9.87B 3.84B 47.89B 3.84B 3.76B 165B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day-1.38%
1 week-2.23%
Current month-3.20%
1 month+22.29%
3 months+38.86%
6 months+51.91%
Current year+39.40%
1 week 20.2
Extreme 20.2
23.12
1 month 14.28
Extreme 14.28
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer 46 28/04/2025
Director TitleAgeSince
Chairman 57 28/04/2025
Director/Board Member 39 28/04/2025
Director/Board Member 48 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/06Free

Director

47,675 0.0966%
09/06Free

Director

34,843 0.0706%
09/06Free

Chairman

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
-1.38%-2.23%+93.09% - 1.28B
+1.70%+7.41%+3.12%+8.46% 49.92B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.86B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +1.82%+5.10%+81.38%+120.30% 24.69B
Weighted average by Cap. +2.05%+6.49%+90.76%+137.74%

Financials

2026 *2027 *
Net sales - -
Net income -173M -151M -139M -130M -246M -16.49B -250M -1.67B -649M -8.11B -650M -636M -27.93B -191M -167M -154M -143M -272M -18.2B -276M -1.84B -717M -8.95B -718M -702M -30.83B
Net Debt -254M -222M -204M -190M -360M -24.14B -366M -2.45B -951M -11.87B -952M -931M -40.89B -300M -262M -241M -225M -426M -28.59B -433M -2.9B -1.13B -14.05B -1.13B -1.1B -48.43B
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
02/07/26 USD 21.51 -1.38% 1,204,531
01/07/26 USD 21.81 -1.85% 861,567
30/06/26 USD 22.22 +0.50% 893,408
29/06/26 USD 22.11 +0.50% 1,122,561
26/06/26 USD 22.00 +0.87% 2,664,341
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
21.51USD
Average target price
48.50USD
Spread / Average Target
+125.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock